From Cypress Bioscience, Developer of Fibromyalgia Drug, Eagerly Awaits FDA Deadline:

cypress_logo
cypress_logo

Cypress Bioscience is developing milnacipran for fibromyalgia

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.